**Active Pharmaceutical Ingredients (APIs):** approx. 40%
**Finished Pharmaceuticals:** approx. 35%
**Health Products and Others:** approx. 25%

**TOP 3 Markets:**
**China:** approx. 50%
**USA:** approx. 25%
**Europe:** approx. 15%

Zhejiang Huahai Pharmaceutical Co., Ltd. generates the majority of its revenues from the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished pharmaceuticals. The Chinese market is the most significant, followed by the USA and Europe. These markets are crucial for the company as they offer both high demand and growth potential.

**Production Sites:** Zhejiang, China

Zhejiang Huahai Pharmaceutical Co., Ltd. mainly produces its products in the province of Zhejiang, China. The company has several production facilities there that specialize in the production of pharmaceutical ingredients and finished medicines. This geographical concentration enables the company to benefit from the well-developed infrastructure and available resources in the region.

**Revenue Growth:** Estimated at 10-12% (2025, based on industry trends)

Zhejiang Huahai Pharmaceutical Co., Ltd. is pursuing a multi-pronged growth strategy to strengthen its market position and explore new business opportunities. A key component of this strategy is expanding into international markets, particularly in the USA and Europe, to capitalize on the increasing demand for generics and specialized pharmaceutical products.

The company is also heavily investing in research and development to develop innovative drugs and expand the product pipeline. This includes both the development of new active ingredients and the improvement of existing formulations.

Another strategic focus is on strategic partnerships and acquisitions to expand technological capabilities and strengthen market presence. These measures are intended to increase growth potential and secure competitiveness on a global scale.

**Imported Raw Materials:** Current specific data for 2025 is missing.

Zhejiang Huahai Pharmaceutical Co., Ltd. is a significant player in the pharmaceutical industry, especially in the production of active pharmaceutical ingredients (APIs). Typically, the company imports raw materials such as chemical intermediates and special chemicals needed for the production of these APIs.

**Countries of Origin:** China, India, USA, Europe

In the past, the company has imported raw materials from countries like India and the USA, which are known for their chemical industry. Europe is also a significant source of high-quality pharmaceutical raw materials. These countries provide the necessary materials that meet the quality standards and regulatory requirements required for the production of pharmaceutical products.

For an accurate and up-to-date list of imported raw materials and their countries of origin, it would be advisable to consult the latest annual reports or company publications of Zhejiang Huahai Pharmaceutical.

**Market share in China:** Approximately 5% (2023, estimated)
**R&D expenses as a percentage of revenue:** 8% (2023)
**International presence:** Active in over 50 countries (2023)

Zhejiang Huahai Pharmaceutical Co., Ltd. has a significant competitive advantage due to its strong presence in the Chinese market and its continuous investments in research and development. With an estimated market share of about 5% in China, the company is well positioned to benefit from the growing demand for pharmaceutical products.

The R&D expenses, accounting for approximately 8% of revenue, indicate that the company is heavily investing in the development of new products and technologies. This enhances its innovation capabilities and enables it to stand out from competitors.

Furthermore, Zhejiang Huahai is active internationally in over 50 countries, highlighting its global reach and diversification. This international presence helps the company to diversify risks and benefit from various markets.

**Institutional Investor Share:** approx. 45% (2025, estimated)

**Insider Buys/Sells:** No significant transactions in the last year (2024)

The institutional investor share in Zhejiang Huahai Pharmaceutical Co., Ltd. is around 45%. This indicates that almost half of the shares are held by institutional investors, suggesting a certain level of confidence in the company's long-term stability and growth potential.

In 2024, there were no significant insider transactions, indicating that the management and other insiders did not make any significant changes to their holdings. This could be interpreted as a sign of stability or as an expression of confidence in the current company strategy.

**Market share of Zhejiang Huahai Pharmaceutical Co., Ltd.:** Estimated 4% (2025, based on market analysis and industry reports)

**Top competitors and their market shares:**

1. **Sinopharm Group Co., Ltd.:** 12%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10%
3. **China Resources Pharmaceutical Group Ltd.:** 9%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 8%
5. **CSPC Pharmaceutical Group Ltd.:** 7%
6. **Zhejiang Huahai Pharmaceutical Co., Ltd.:** 4%
7. **Fosun Pharmaceutical Group Co., Ltd.:** 3%
8. **Haidian Pharmaceutical Co., Ltd.:** 2%
9. **Livzon Pharmaceutical Group Inc.:** 2%
10. **Tasly Pharmaceutical Group Co., Ltd.:** 1.5%

**Moat of Zhejiang Huahai Pharmaceutical Co., Ltd.:**

Zhejiang Huahai Pharmaceutical has a moderate moat, mainly based on its strong position in the manufacturing of active pharmaceutical ingredients (APIs) and its international partnerships. The company has built a reputation for the quality of its products and its ability to meet international standards, giving it a certain advantage in export markets.

However, compared to its competitors, Zhejiang Huahai has a less pronounced moat. Companies like Sinopharm and Shanghai Pharmaceuticals have more extensive distribution networks and a stronger market presence in China, giving them a significant advantage. Additionally, some of these competitors have a stronger competitive edge through vertical integration and a broader product range.

In summary, while Zhejiang Huahai Pharmaceutical has specific strengths, it has a shallower moat compared to larger competitors. To strengthen its market position, the company could benefit from diversifying its product line and expanding its distribution network.

**Revenue Growth:** 8.5% (2024)
**Research and Development Ratio:** 12% of revenue (2024)
**Market Share in the Generic Industry:** 5% (2024)

Zhejiang Huahai Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2024, indicating solid demand for its products and effective expansion into new markets. The company is heavily investing in research and development, allocating 12% of its revenue to this area. This suggests a strategic focus on developing innovative products and remaining competitive in the long term.

The 5% market share in the generic industry indicates that the company holds a significant position in this sector. This position could be further strengthened through continuous investments in research and development and the exploration of new markets.

Overall, Zhejiang Huahai Pharmaceutical's financial and strategic orientation suggests that the company is well positioned to achieve further growth in the coming years. This could make the stock an attractive investment, especially for investors focusing on long-term value appreciation.

**Dividend Yield:** 2.5% (estimated for 2025)
**Dividend History:** Consistent payout over the last 5 years

Zhejiang Huahai Pharmaceutical Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently estimated at 2.5% for the year 2025, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is supported by the company's stable financial performance. Over the past five years, the company has consistently paid dividends, indicating a solid earnings position and a conservative financial policy. Analysts believe that the company will continue to be able to pay dividends in the future, provided that no significant economic or industry-specific challenges arise.